Mounjaro®
Starting from £179.99/mo
Start journey Learn moreChocolate cravings on Wegovy don't always disappear the moment treatment starts. Many people notice their appetite shrinks significantly, yet a specific pull towards something sweet — chocolate in particular — hangs around. That's not a sign the medicine isn't working. Semaglutide, the active ingredient in Wegovy, reduces overall hunger through GLP-1 receptor activation, but it doesn't neutralise every craving equally, and understanding why helps you make a better decision about what to do next. Wegovy is a prescription-only medicine; a clinical prescriber decides whether it's right for you, and the guidance below is educational rather than a substitute for that assessment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy works primarily by activating GLP-1 receptors in the gut and brain, slowing gastric emptying and signalling fullness more strongly after meals. For most people this produces a noticeable drop in background hunger, the low-grade appetite that used to prompt snacking throughout the day. But chocolate cravings are a different animal. They're driven partly by the brain's dopamine-based reward system, which responds to the sensory qualities of food: sweetness, fat content, the specific texture of chocolate melting. GLP-1 receptor agonists modulate some of these pathways too, which is why many people on semaglutide report less interest in ultra-processed foods over time. The operative phrase is over time. Early in treatment, or at lower doses, the reward pull towards chocolate can persist even as overall portion sizes shrink.
There's also a practical dimension. When you're eating considerably less, it's easy to under-eat protein and fibre. Both stabilise blood sugar. A dip in blood sugar (even a modest one) reliably increases the brain's preference for fast-release carbohydrates. Chocolate, with its combination of sugar and fat, answers that signal loudly. This doesn't make the craving a character flaw; it makes it a signal worth paying attention to. The semaglutide overview has more on how the medicine interacts with these appetite mechanisms.
For anyone exploring how Wegovy works more broadly, including those curious about how Wegovy is approved and used across the EU, the Wegovy treatment page covers the full licensed context.
The most useful reframe is treating a chocolate craving as a piece of information rather than a test of willpower. Ask: have you eaten enough protein today? NHS guidance on healthy weight consistently points to protein and fibre as the nutrients most likely to sustain satiety between meals. On Wegovy, reduced appetite can compress eating windows to the point where these nutrients get crowded out. A small, protein-rich snack taken alongside or shortly before the craving usually reduces its intensity within twenty minutes.
If chocolate itself is what you want, portion context matters more than outright avoidance. A couple of squares of dark chocolate (70% cocoa or higher) delivers magnesium and has less added sugar than milk chocolate. Eaten slowly, after a meal rather than in isolation, it has a much smaller effect on blood sugar than the same calories of milk chocolate consumed on an empty stomach. The goal isn't perfect eating; it's noticing patterns and making the next choice slightly easier.
Cravings for sweets more generally (not just chocolate) are common on GLP-1 treatment. The page on craving sugar on Wegovy covers the broader picture, and there's a dedicated look at how cravings shift during treatment if you want the wider context.
For most people, chocolate cravings ease as dose titration progresses. The Wegovy schedule starts at 0.25mg and moves upward at roughly four-week intervals; many people notice the sharpest shift in food preferences at higher maintenance doses. If you're still early in treatment, patience and nutritional attention are often enough.
Cravings that feel compulsive, that are connected to difficult emotions, or that drive eating patterns that worry you deserve a clinical conversation rather than a self-help strategy. Your prescriber can help distinguish between a nutritional pattern and something that warrants additional support, including onward referral where appropriate. At nume, at our pharmacy, clinician contact isn't just for the initial prescription. Aftercare is included. Every repeat supply is reviewed by a real prescriber who can address questions like this one.
On the cost side, if you're weighing up whether ongoing treatment is financially manageable, the Wegovy cost page lays out what's typically included in a private prescription price and what to check for. Treatment is prescription-only through a clinical assessment; you can start a free consultation to see whether Wegovy suits your situation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.